Olema Pharmaceuticals, Inc. — Director's Dealing 2021

Dec 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Olema Pharmaceuticals, Inc. (OLMA)
CIK: 0001750284
Period of Report: 2021-12-10

Reporting Person: Myles David C. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-10	Common Stock	S	10000	$10.30	Disposed	582901	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12831	Indirect
Common Stock	154846	Indirect

Footnotes

F1: T he weighted average sale price for the transaction reported was $10.30, and the range of prices was between $10.23 and $10.50. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F2: Includes 589 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021, and 491 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021.

F3: The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.

F4: The shares are held by Myles Properties Inc., of which the Reporting Person is President.